AzTrials
AzTrials

Coronary DiseaseNCT05455515

The GISE (Società Italiana di Cardiologia Interventistica) - ShockCalcium Registry

An observational study of Coronary Disease, run by Fondazione GISE Onlus at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The GISE-SHOCKCALCIUM Registry is an Investigator Driven Italian All Comers prospective, observational, multicenter Italian IVL registry of Calcified lesions Treated with Intravascular Lithotripsy. The main purpose is to evaluate the efficacy and safety of coronary lithotripsy for treatment of severe calcified lesion. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Disease
What is being tested?
IVL procedures
Type of treatment
Surgery or procedure
How many people
2,000 participants
Where
1 siteItaly
Study dates
17 Sep 2022to 1 Aug 2026
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: patients with coronary calcified lesions

Who may be able to join

  • Patients is ≥ 18 years of age.
  • Patients with calcified coronary artery disease requiring percutaneous revascularization with stent implantation who require an IVL with the Shockwave catheter.
  • Presence of single or multiple calcifications at the lesion site defined by,
  • angiography, with fluoroscopic radio-opacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location and total length of calcium of at least 15 mm and extending partially into the target lesion, OR by b) IVUS or OCT, with presence of ≥270 degrees of calcium on at least 1 cross section
  • Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel, prasugrel, or ticagrelor for 1 year and single antiplatelet therapy for life)
  • Ability to give written informed consent.
  • Patient is able and willing to comply with all follow-up assessments

Who cannot join

  • Refusal to participate in this study.
  • Calcific lesion within a > 4 mm reference segment of the vessel
  • Lesions in LIMA(left internal mammary artery)/RIMA (rightinternal mammary artery) or at the distal anastomosis of an SVG (saphenous vein grafts)
  • All the usual relative contraindications to coronary angioplasty according to the clinical practice:
  • Patient has active systemic infection
  • Patient has a known untreated coagulation disorder
Show all 10Show fewer
  • Patient has allergy to imaging contrast media for which he/she cannot be pre-medicated
  • Patient is pregnant or nursing
  • Patients whose life expectancy is < 1 year
  • Patients due to move abroad within 1 year

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • University Hospital Careggi Florence

    Florence

    Carlo Di Mario, +393486522399, carlo.dimario@unifi.it

    Recruiting

Other trials in Italy

About this study

Official title: The GISE-ShockCalcium Registry - An Investigator Driven Italian All Comers Registry of Calcified Lesions Treated With Intravascular Lithotripsy

The GISE-SHOCKCALCIUM Registry is an Investigator Driven Italian All Comers prospective, observational, multicenter Italian IVL registry of Calcified lesions Treated with Intravascular Lithotripsy. The main purpose is to evaluate the efficacy and safety of coronary lithotripsy for treatment of severe calcified lesion. A total of 2000 patients with coronary calcified lesions will be enrolled in 24 months. The registry will be conducted in approximately 50 interventional cardiology centers in Italy with at least 2 IVL procedures per 24 months. Primary endpoint: Target lesion failure (TLF) at 1 year.

Secondary safety endpoints: in Hospital Target lesion failure (TLF); Target Lesion Failure at 30 days; definite or probable stent thrombosis; procedural angiographic safety endpoints. Secondary effectiveness endpoints: device crossing and IVL delivery success; angiographic success; QCA (quantitative coronary angiography) outcome; Imaging outcome.

Read the detailed description

This is a prospective, observational, multicenter Italian IVL registry designed to evaluate the efficacy and safety of coronary lithotripsy for treatment of severe calcified lesion.

This registry is planned to be conducted at approximately 30-50 sites in Italy and to include a total of 2000 patients with coronary calcified lesions.

The Principal Investigators will approach all the Italian centers with at least 2 IVL procedures per month via the regional GISE Coordinator and based on the IVL volume of the various hospitals with IVL in the previous 18 months (excluding the period February-June 2020). Possible regulatory or budgetary constrictions expected to limit future application of IVL will also be considered. Centers should be approached by on-line questionnaires and during regional teleconferences to agree to collect data for all IVL procedures, fill a screening log for all calcified lesions, perform a complete clinical 1 year follow-up of all IVL patients, including collection of source documents for event adjudication. Participation in OCT (optical coherence tomography) or IVUS (Intravascular UltraSound) sub-studies (clinically mandated imaging) will be highly encouraged agreeing to perform documented pull-backs across the calcified treated/stented segment and provide images for off-line analysis from a central core laboratory.

The registry will consist of 3 essential parts: a screening period (patient and lesion selection), a treatment period (PCI with IVL lesion preparation and stent implantation), and a follow-up period (1 year).

Patients will be screened, according to the flowchart and stratified at baseline by angiographic evaluation or intravascular imaging.

Patients will be scheduled to undergo an intracoronary lithotripsy procedure using an appropriately sized Shockwave catheter (Shockwave Medical, Fremont, CA).

All arteries with visible calcium with the appearance of facing lines in at least one view will be included in the registry. In calcified lesions with questionable indications (not too long/thick angiographically) the use of IVUS or OCT will be strongly encouraged, but final selection will be left at the Investigators' preference. IVUS should be used instead of OCT in the presence of CKD (chronic kidney disease) and for very distal or aorto-ostial stenoses, all relative or absolute contraindications for OCT.

Selection of additional devices (Rotablator, IVL, high pressure or cutting/scoring balloons) will also be performed at the Investigators' preference.

Lesions with angiographically severe calcification will be examined with QCA analysis and/or intravascular imaging in order to discriminate between lesions requiring direct treatment with IVL and lesions treatable with balloon pre-dilatation. IVL could be also performed in case of focal balloon under-expansion, defined as the persistence of a focal balloon indentation 28at a pressure of 16-18 Atm, in lesions with angiographically mild to moderate calcifications or no angiographically visible calcifications initially planned for conventional balloon pre-dilatation. Uncrossable lesions will receive RA (Rotablator atherectomy) as default strategy, with an option for IVL in case of suboptimal balloon expansion.

The sample size was estimated by considering the primary endpoint of the study, i.e., the comparison of the late (one year) composite endpoint of CV (cardiovascular) death, lesion-related MI (Myocardial infarction), TLF including clinically driven TLR (Target lesion revascularization), definite and probable ST (stent thrombosis) in IVL treatment compared to other interventions. A Monte Carlo (MC) simulation method was considered for the calculation. According to a sample size up to 2000 patients, a study size of 1900 patients for a 12% event ensures an average confidence interval length of 0.029 (Figure 4). The final sample size is 2000 adjusted for a 5% dropout rate.

Being tested
IVL procedures
Medical subject headings
Coronary Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IVL proceduresProcedure or surgery

    Intravascular Lithotripsy (IVL)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary composite safety endpoint: Target lesion failure (TLF): cardiovascular death

    Cardiovascular death defined as death resulting from cardiovascular causes:

    1. death caused by acute MI
    2. death caused by sudden cardiac arrest, including unwitnessed death
    3. death resulting from heart failure
    4. death caused by stroke
    5. death caused by cardiovascular procedures
    6. death resulting from cardiovascular hemorrhage
    7. death resulting from other cardiovascular cause

    Measured: at 1 year

  2. Primary composite safety endpoint: Target lesion failure (TLF): Target-vessel Myocardial infarction (TV-MI)

    based on CK-MB level >3x ULN with or without new pathologic Q-wave through discharge (peri-procedural MI) and using the 4th Universal Definition of MI beyond discharge

    Measured: at 1 year

  3. Primary composite safety endpoint: Target lesion failure (TLF): Target lesion revascularization (TLR)

    defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion, clinically or ischemia driven

    Measured: at 1 year

Secondary outcomes (6)
  1. Secondary safety endpoints: in Hospital Target lesion failure (TLF)

    defined as a composite of cardiac death, target vessel related non-fatal myocardial infarction or need for unplanned target lesion revascularization

    Measured: at 1 year

  2. Secondary safety endpoints: Target lesion failure

    defined as a composite of cardiac death, target vessel related non-fatal myocardial infarction or need for unplanned target lesion revascularization

    Measured: at 30 days

  3. Secondary safety endpoints: Definite or probable stent thrombosis

    Definite stent thrombosis (ST) OR Pathological confirmation of ST determined by the evidence of recent thrombus within the stent at autopsy and/or examination of tissue retrieved following thrombectomy (visual/histology).

    Probable ST: Regardless of the time after the index procedure, any myocardial infarction that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent/scaffold thrombosis and in the absence of any other obvious cause)25.

    Timing of ST:

    Acute 0*-24h Subacute >24h-30day Late 30 day-1 year

    *0 is defined as the moment the patient is undraped and taken off the catheterization table25

    Measured: at 1 year

  4. Secondary safety endpoints: Procedural angiographic safety endpoints

    1. severe dissection: dissection in the target vessel greater than type B from National Heart, Lung, and Blood Institute classification
    2. coronary perforation defined as evidence of extravasation of dye or blood from the coronary artery during or following the interventional procedure. This is detected either by angiographic appearances consistent with dye outside of the vessel lumen or by echocardiographic evidence of a pericardial effusion.
    3. abrupt closure defined as an abrupt cessation of coronary flow to TIMI grade 0 or 1 flow before or at ≤5 mm distal to the lesion in an artery in which PTCA was attempted where there had previously been TIMI grade 2 or 3 flow prior to the procedure.
    4. slow flow or no-reflow: markedly delayed flow (TIMI grade 2 for slow flow, TIMI 0 or 1 for no reflow) in a target vessel with minimal (<30%) residual stenosis at the stented/scaffolded segment and no evidence of flow-limiting dissection

    Measured: at 1 year

  5. Secondary effectiveness endpoints: Device crossing and IVL delivery success

    defined by the ability to deliver the IVL catheter across the target lesion prior or after pre-dilatation and delivery of lithotripsy without serious arrhythmias during delivery or angiographic complications after IVL

    Measured: at 1 year

  6. Secondary effectiveness endpoints: Angiographic success

    Stent delivery with ≤30% residual stenosis and without serious angiographic complications

    Measured: at 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2022
  2. Study start17 Sep 2022
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
2,000 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT05455515
Sponsor's protocol ID
GISE_Shockcalcium
Status last verified
Mar 2024
First submitted
20 May 2022
Last updated
4 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Disease, run by Fondazione GISE Onlus at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary composite safety endpoint: Target lesion failure (TLF): cardiovascular death (time frame: at 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in